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Abstract
Background: Lymph node status is one prognostic factor in head and neck cancer. The purpose of this study is to
investigate the prognostic value of lymph node ratio (LNR) in head and neck cancer patients who received surgery
plus postoperative chemoradiotherapy.
Methods: From May 1991 to December 2012, a total of 117 head and neck cancer patients who received surgery
plus postoperative chemoradiotherapy were analyzed. The primary sites were oral cavity (93), oropharynx (13),
hypopharynx (6), and larynx (5). All patients had pathologically confirmed squamous cell carcinoma and 63 patients
had neck lymph nodes metastasis. LNR was calculated for each patient. The endpoints were overall survival (OS),
local failure-free survival (LFFS), and distant metastasis-free survival (DMFS).
Results: The median follow up time was 36 months, with a range from 3.4 to 222 months. The 3-year rates of OS,
LFFS, and DMFS were 59.7, 70.3, and 81.8 %, respectively. The median value of LNR for lymph nodes positive
patients was 0.1. In univariate analysis, patients with an LNR value less than 0.1 had better 3-year OS (67.0 %
vs.41.0 %, p = 0.004), 3-year LFFS (76.1 % vs. 54.9 %, p = 0.015) and 3-year DMFS (87.2 % vs. 66.4 %, p = 0.06).
Multivariate analysis revealed that LNR was an independent prognostic factor for OS (hazard ratio [HR] = 2.92;
95 % confidence interval [CI] = 1.367–6.242; p = 0.006) and LFFS (HR = 4.12; 95 % CI = 1.604–10.59; p = 0.003).
Conclusion: LNR is an important prognosis factor for OS and LFFS in head and neck cancer patients.
Background
Squamous cell carcinoma (SCC) of head and neck is one
of the common malignant tumors worldwide. The main-
stay of treatment is surgery; surgery plus chemotherapy
and/or radiotherapy are used for treatment of advanced
disease [1–3]. However, even after patients receive sur-
gery plus adjuvant therapy for head and neck cancer,
some of them may still experience relapse. Therefore, it
is important to improve treatment outcome by finding
reliable prognostic factors and identifying head and neck
cancer patients at high risk of relapse.
One of the most commonly used prognostic factors
is the tumor-node-metastasis (TNM) staging system.
The TNM staging system classifies lymph nodes status
by the number, size, and laterality of positive lymph
nodes [4]. However pathologic lymph node status and
current nodal classification may not necessarily predict
prognosis [5].
Lymph nodes ratio (LNR), defined as the ratio of the
number of positive lymph nodes to the total number of
lymph nodes removed, is used as a prognostic factor in
patients with bladder cancer [6, 7], esophageal cancer [8]
and cervical cancer [9]. Some studies [10–13] showed
that LNR could predict the clinical outcomes in head
and neck cancer patients.
The purpose of this study was to investigate the prog-
nostic value of LNR in head and neck cancer patients who
received surgery plus postoperative chemoradiotherapy.
Materials and methods
Patients
We reviewed the database of patients who were newly
diagnosed with head and neck cancer from May 1991 to
December 2012 at Taichung Veteran General Hospital.
The inclusion criteria were patients: (1) who underwent
a complete pretreatment staging workup, and had no
distant metastasis at diagnosis; (2) with pathologically
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confirmed SCC; (3) who received radical tumor excision
with adequate margin and neck dissection; and (4) who
received adjuvant chemoradiotherapy. There were 117
eligible patients in this cohort study. Pathologic lymph
node status was evaluated by 2 pathologists and LNR
was calculated for each patient. The final staging was
done according to the American Joint Committee on
Cancer (AJCC) TNM classification system 7th edition.
The study was approved by the Institutional Review
Board of Taichung Veterans General Hospital.
Chemoradiotherapy
All patients were scheduled to undergo external beam
radiotherapy using a linear accelerator with a 6-MV
photon beam and source-axis distance technique. A total
radiation dose of 60.0–73.8 Gy, 1.8–2.0 Gy per fraction,
5 fractions per week was delivered. A radiation does of
60–70 Gy was used in all patients except one, who re-
ceived 73.8 Gy.
Concurrent chemotherapy consisted of cisplatin
20 mg/m2 and 5FU 400 mg/m2 for 1–4 days, during the
first and fifth week of radiotherapy, or weekly cisplatin
30–50 mg/m2.
Statistical analysis
The endpoints were overall survival (OS), local failure-
free survival (LFFS) and distant metastasis-free survival
(DMFS). The OS was calculated from the date of sur-
gery to the date of death from any cause or last follow-
up. The LFFS was measured from the date of surgery to
the date of any evidence of local recurrence or last
follow-up. The DMFS was calculated from the date of
surgery to the date of distant metastasis or last follow-
up. We analyzed the impact of LNR on OS, LFFS, and
DMFS. Survival times were estimated using the Kaplan-
Meier method and Log-rank test was used for the com-
parison between the groups. A Cox regression model
was used for multivariate analysis. The statistical ana-
lyses were performed using SPSS software, version 10.0.
A p value less than 0.05 was considered statistically
significant.
Results
Table 1 summarizes the patients’ characteristics. There
were 110 males and 7 females. The median age was
51 years, with a range from 34–74 years. The primary
site included the oral cavity (93), oropharynx (13), hypo-
pharynx (6), and larynx (5). Histopathologic examination
revealed that 35 patients had positive margin, 63 patients
had lymph nodes metastasis, and 25 patients had extra-
capsular extension.
Additional file 1: Table S1 showed the absolute num-
ber of lymph nodes metastases and LNR distribution of
all patients. The absolute number of metastatic lymph
node ranged from 1 to 15. Twenty patients had single
lymph node metastasis and 43 patients had 2 or more
lymph nodes metastases. The median value of LNR for
lymph node-positive patients was 0.1, with a range from
0.01 to 1.0. We categorized all patients into LNR ≧ 0.1
group and LNR < 0.1 group. Patients with negative
lymph nodes were assigned to the LNR < 0.1 group.
There were 84 patients in the LNR < 0.1 group, and 33
patients in the LNR ≧ 0.1 group. For 63 lymph node-
positive patients, we divided these patients into high
(LNR > 0.17), medium (LNR: 0.06–0.17) and low (LNR <
0.06) LNR group.
The median follow-up time was 36 months, with a
range from 3.4 to 222 months. For surviving patients,
the follow up time was at least 2 years. The 3-year OS,
LFFS, and DMFS for all patients were 59.7, 70.3, and
81.8 %, respectively. There were no treatment-related
death in this study. Table 2 summarizes the results of
univariate analysis. Patients with LNR <0.1 had longer 3-
year OS (67.0 % vs.41.0 %, p = 0.004, Fig. 1). Patients
with LNR <0.1 had higher 3-year LFFS (76.1 % vs.
54.9 %, p = 0.015, Fig. 2). Patients with LNR <0.1 tended
to have better 3-year DMFS (87.2 % vs. 66.4 %, p = 0.06,
Fig. 3). The subgroup analysis for lymph node-positive
patients showed that higher LNR had poor 3-year OS
(p = 0.003, Fig. 4) and LFFS (p = 0.011, Fig. 5). High
LNR group had poorer DMFS than medium and low
LNR group (Fig. 6), but it did not reached statistically
significance (p = 0.18). The absolute number of lymph
node metastases had no significant difference on OS
(p = 0.28), LFFS (p = 0.46) and DMFS (p = 0.96).
To investigate whether LNR was an independent
prognostic factor for OS, LFFS and DMFS for head and










Lymph nodes status Positive 63
Negative 54
Extracapsular extension Positive 25
Negative 92
Lymph nodes ratio <0.1 84
≧0.1 33
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neck patients, we conducted a multivariate analysis
with relevant variables. Table 3 summarizes the results
of the multivariate analysis. LNR was an independent
prognostic factor for OS (hazard ratio [HR] = 2.92; 95 %
confidence interval [CI] = 1.367–6.242; p = 0.006) and
LFFS (HR = 4.12; 95 % CI = 1.604–10.59; p = 0.003).
LNR also showed borderline statistically difference on
DMFS (HR = 3.10; 95 % CI = 0.957–10.09; p = 0.059).
Discussion
Surgery is the mainstay treatment for head and neck
cancer, and the standard operation for head and neck
cancer patients is resection of primary tumor with ad-
equate margins for local control and neck dissection for
neck control. One of the most significant prognostic fac-
tors is neck lymph nodes metastasis [14]. In the study by
Mamalle et al. [14], the number of positive lymph nodes
was found to be a predictor of outcome for head and
neck cancer patients. Previous studies [15, 16] showed
that a significantly likelihood of finding neck lymph
nodes metastasis was associated with increased in the
total number of dissected lymph nodes. But Gil et al.
[10] found no significant correlation between the total
number of excised lymph nodes (positive and negative)
and the number of positive lymph nodes in the speci-
men. The number of positive lymph nodes and the total
number of dissected lymph nodes are affected by a
lymph nodes dissection procedure and confirmed by
Fig. 1 Overall survival according to lymph nodes ratio for
all patients
Fig. 2 Local failure free survival according to lymph nodes ratio for
all patients
Table 2 Univariate analysis for three- year LFFS, DMFS, and OS
Parameter LFFS (%) DMFS (%) OS (%)
Age
≦51 61.3 76.1 58.4
> 51 79.9 88.0 63.4
p = 0.02 p = 0.13 p = 0.76
Tumor site
Oral cavity 64.8 81.7 56.4
others 88.0 82.9 70.4
p = 0.06 p = 0.46 p = 0.28
Stage
I + II 80.2 100 71.5
III + IV 68.3 76.6 57.4
p = 0.23 p = 0.04 p = 0.13
Margin
Positive 64.6 89.5 41.0
Negative 73.3 79.2 67.6
p = 0.85 p = 0.14 p = 0.05
Extracapsular extension
Positive 68.7 77.0 64.0
Negative 70.8 83.4 58.6
p = 0.76 p = 0.93 p = 0.11
LNR for all patients
< 0.1 76.1 87.2 67.0
≧0.1 54.9 66.4 41.0
p = 0.015 p = 0.06 p = 0.004
LNR for lymph node-positive
patients
< 0.06 75.6 94.1 77.8
0.06–0.17 74.8 71.1 59.7
> 0.17 24.2 57.3 23.5
p = 0.011 p = 0.18 p = 0.003
Absolute number of lymph
node metastasis
1 60.0 75.8 48.5
> 1 66.4 76.6 58.0
p = 0.46 p = 0.96 p = 0.28
OS overall survival, LFFS local failure-free survival, DMFS distant metastasis-free
survival, LNR lymph node ratio
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pathological examination. The LNR may have a higher
prognostic value in determining lymph nodes status, be-
cause disease (the number of positive lymph nodes),
treatment option (neck dissection procedure and total
number of dissected lymph nodes) and the diagnosis of
a pathologist are considered at the same time.
To our knowledge, few studies analyzed LNR in pa-
tients with different head and neck cancer. Gil et al. [10]
analyzed 386 oral cavity cancer patients who received
primary surgery with or without adjuvant radiotherapy
and showed LNR remained the only independent pre-
dictor of OS (HR = 2.0, p = 0.02), disease specific survival
(DSS) (HR = 2.3, p = 0.02), and local control (HR = 4.1,
p = 0.005). Kim et al. [11] analyzed 211 oral cavity can-
cer patients who underwent surgery and found that
LNR was an independent predictor of DSS (HR = 3.24,
95 % CI = 1.61–6.53; p = 0.001). In our study, we found
LNR was an independent prognostic factor for OS
(HR = 5.14; 95 % CI = 2.026–13.07; p = 0.001) and LFFS
(HR = 12.60; 95 % CI = 3.872–37.5; p < 0.001) for head
and neck cancer patients who received surgery and ad-
juvant chemoradiotherapy.
The cutoff value for LNR varied across studies. Gil
et al. [10] used a cutoff value of 0.06. Sayed et al. [13]
reviewed medical data of 1408 oral cancer patients and
found LNR (0.088) was significantly associated with sur-
vival outcomes. Hua et al. [12] analyzed 81 hypopharyn-
geal cancer patients and revealed that those with an
LNR ≧ 0.1 had poor OS. In our study, we used a cutoff
value of 0.1 to categorize patients into LNR ≧ 0.1 group
and LNR < 0.1 groups. Shrime et al. [17] categorized oral
SCC patients into low (0–6 %), moderate (6–13 %) and
high (>13 %) risk groups based on nodal ratio. Ebrahimi
et al. [18] used multiple LNR cutoff points to analyze
survival outcomes of oral cancer patients who received
surgery and discovered that LNRs are important in prog-
nostic models for node‐positive patients. Previous stud-
ies did not define a specific cutoff value for LNR, but
patients with a higher LNR were shown to have poor
survival.
This retrospective study had some limitations. First,
different primary sites and different operation proce-
dures may have affected the treatment results. Second,
the total number of dissected lymph nodes depended on
disease and physicians’ lymph node criteria, this may
have affected the LNR results. The main advantage of
this study was that all patients received surgery plus
Fig. 5 Local failure free survival according to lymph nodes ratio for
63 lymph node-positive patients
Fig. 6 Distant metastasis free survival according to lymph nodes
ratio for 63 lymph node-positive patients
Fig. 4 Overall survival according to lymph nodes ratio for 63 lymph
node-positive patients
Fig. 3 Distant metastasis free survival according to lymph nodes
ratio for all patients
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adjuvant chemoradiotherapy. Compared to previous
study, our treatment was more consistent. Consistent
adjuvant therapy can reduce the effects of different treat-
ments. Further study is needed to confirm the prognos-
tic value of LNR in head and neck cancer patients.
Conclusion
LNR is an independent prognosis factor for OS and
LFFS in head and neck cancer patients. In addition to
the AJCC TNM classification system, LNR may be use-
ful in stratifying risk in patients with head and neck
cancer.
Additional file
Additional file 1: Table S1. The LNR distribution of all patients. (DOC 221 kb)
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